GXMC
BMRN icon

Global X Management Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Global X Management Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,891
Closed -$153K – 1178
2018
Q1 		$153K Sell
1,891
-253
-12% -$21.7K ﹤0.01% 937
2017
Q4 		$191K Sell
2,144
-129
-6% -$11.2K ﹤0.01% 789
2017
Q3 		$212K Buy
2,273
+338
+17% +$29.9K 0.01% 771
2017
Q2 		$176K Buy
1,935
+279
+17% +$25.4K 0.01% 818
2017
Q1 		$145K Buy
1,656
+619
+60% +$55.1K 0.01% 815
2016
Q4 		$86K Buy
1,037
+459
+79% +$39.5K ﹤0.01% 836
2016
Q3 		$53K Buy
578
+198
+52% +$18.6K ﹤0.01% 854
2016
Q2 		$30K Buy
380
+2
+0.5% +$170 ﹤0.01% 810
2016
Q1 		$31K Buy
378
+336
+800% +$27.3K ﹤0.01% 672
2015
Q4 		$4K Buy
42
+10
+31% +$1.04K ﹤0.01% 699
2015
Q3 		$3K Buy
32
+2
+7% +$267 ﹤0.01% 825
2015
Q2 		$4K Buy
+30
New +$3.72K ﹤0.01% 762

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Global X Management Company's BMRN Position: Q2 2018 in Review

Global X Management Company sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 1,891 shares — an estimated $153K sold.

Global X Management Company first reported a position in BMRN in Q2 2015 and held it in 12 quarters. The position peaked at $212K in Q3 2017. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • Global X Management Company reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Global X Management Company sold 1,891 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $153K.
  • Global X Management Company first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 12 quarters.
  • Global X Management Company's BioMarin Pharmaceuticals position peaked at $212K in Q3 2017.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Global X Management Company's 13F filing for Q2 2018, filed 16 Aug 2018.